Cargando…

Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA

The introduction of point-of-care (POC) assays into clinical practice in patients with inflammatory disease enables on-demand therapeutic decision making. The aim of this study was to compare the POC test Quantum blue (Bühlmann Laboratories) for infliximab (IFX), adalimumab (ADL), and its anti-drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toja-Camba, Francisco José, García-Quintanilla, Laura, Rodríguez-Martinez, Lorena, Tomine, Julia, Cajade-Pascual, Francisco, Feitosa, Carolina, Zarra-Ferro, Irene, Barreiro-De-Acosta, Manuel, González-López, Jaime, Mondelo-García, Cristina, Fernández-Ferreiro, Anxo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675023/ https://www.ncbi.nlm.nih.gov/pubmed/38004593 http://dx.doi.org/10.3390/pharmaceutics15112615

Ejemplares similares

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
por: García-Quintanilla, Laura, et al.
Publicado: (2019)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
por: Toja-Camba, Francisco José, et al.
Publicado: (2021)

Ampicillin Stability in a Portable Elastomeric Infusion Pump: A Step Forward in Outpatient Parenteral Antimicrobial Therapy
por: Rodríguez-Martínez, Lorena, et al.
Publicado: (2023)

A Review of Population Pharmacokinetic Analyses of Linezolid
por: Bandín-Vilar, Enrique, et al.
Publicado: (2022)

Ocular Biodistribution Studies Using Molecular Imaging
por: Castro-Balado, Ana, et al.
Publicado: (2019)

Recent Research in Ocular Cystinosis: Drug Delivery Systems, Cysteamine Detection Methods and Future Perspectives
por: Castro-Balado, Ana, et al.
Publicado: (2020)

Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence
por: Castro-Balado, Ana, et al.
Publicado: (2022)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

Recent Advances in Proteomics-Based Approaches to Studying Age-Related Macular Degeneration: A Systematic Review
por: García-Quintanilla, Laura, et al.
Publicado: (2022)

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
por: Neovius, M, et al.
Publicado: (2015)

Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab
por: Gorovits, B., et al.
Publicado: (2018)

Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
por: Rissel, Florian, et al.
Publicado: (2023)

Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review
por: Busto-Iglesias, Manuel, et al.
Publicado: (2023)

Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems, Part II: Long-Term Stability and Clinical Ocular Biopermanence
por: Castro-Balado, Ana, et al.
Publicado: (2023)

A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn’s Disease Treated with Adalimumab or Infliximab
por: Yokoyama, Kaoru, et al.
Publicado: (2016)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Adalimumab/infliximab: Lower serologic response: 6 case reports
Publicado: (2022)

Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis
por: Mase, Oliver, et al.
Publicado: (2023)

Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels
por: Jani, Meghna, et al.
Publicado: (2016)

Proactive Drug Monitoring Is Associated With Higher Persistence to Infliximab and Adalimumab Treatment and Lower Healthcare Utilization Compared With Reactive and Clinical Monitoring
por: Syed, Nauroz, et al.
Publicado: (2020)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations
por: Varela-Fernández, Rubén, et al.
Publicado: (2020)

Efficacy and Safety of Inhaled Ethanol in Early-Stage SARS-CoV-2 Infection in Older Adults: A Phase II Randomized Clinical Trial
por: Castro-Balado, Ana, et al.
Publicado: (2023)

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
por: Carlsen, Arne, et al.
Publicado: (2018)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Efficacy of infliximab and adalimumab therapy in very early onset, severe ulcerative colitis
por: Rohani, Pejman, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
por: Gholami, Ahmad, et al.
Publicado: (2021)

Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis
por: Mori, Ayano, et al.
Publicado: (2020)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
por: Barberio, Brigida, et al.
Publicado: (2020)

Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database
por: Maity, Tuhin, et al.
Publicado: (2021)

Use of Adalimumab in young patients with chronic uveitis in whom infliximab loses its efficacy
por: Giani, TG, et al.
Publicado: (2008)

Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study
por: Thorne, Carter, et al.
Publicado: (2017)

Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay
por: Papamichael, Konstantinos, et al.
Publicado: (2020)

Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
por: Campanilho-Marques, Raquel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ebfk1bcvj20e94596f04bdi2gb